Beyond IDO1: Systems-Level Insights Into Enzymatic Networks And Regulatory Mechanisms In Cancer Immunotherapy Resistance

Meera Indracanti[1]*, Muni Kumar Dokka[2], Madhumita Panda[3], Padmaja Musunuri[4], Nagendra Babu Gundamraju[5]

[1]Professor, Department of Medical Biotechnology, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.
[2]Associate Professor, Department of Biochemistry, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.
[3]Assistant Professor, Department of Medical Biotechnology, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.
[4]Assistant Professor, Department of Biochemistry, Government College for Women (A), Guntur, Andhra Pradesh, India.
[5]Professor, Department of Biochemistry, School of Allied and Healthcare Sciences, Malla Reddy University, Hyderabad, Telangana, India.
**Corresponding Author: Meera Indracanti*
**E mail: drmeera@mallareddyuniversity.ac.in*

Keywords: Cancer immunotherapy, enzymatic compensation, IDO1 inhibitors, immunotherapy resistance, network-based therapeutics.

ABSTRACT

Background: Cancer immunotherapy resistance affects 60-80% of patients receiving immune checkpoint inhibitors. The failure of IDO1 inhibitors in ECHO-301—despite achieving >90% target engagement—revealed critical gaps in understanding immunosuppressive networks that drive therapeutic resistance.

Methods: We synthesized evidence from clinical trials, molecular studies, and systems biology approaches to characterize enzymatic compensation networks underlying immunotherapy resistance. We analyzed three interconnected resistance mechanisms: enzymatic compensation circuits, upstream regulatory rewiring, and spatial-temporal network organization.

Results: Immunotherapy resistance operates through sophisticated enzymatic compensation circuits rather than isolated pathway dysfunction. When IDO1 is inhibited, alternative pathways involving IL4I1, TDO, GLS1, and CD73 rapidly activate to maintain immunosuppressive function. These networks are controlled by upstream regulatory mechanisms including epigenetic reprogramming, post-translational modifications, and non-coding RNA circuits. Novel targets offer distinct network disruption opportunities through alternative metabolic pathways and dual regulatory functions.

Conclusions: Success requires rational combination strategies targeting multiple network nodes simultaneously, upstream interventions modulating regulatory networks, and precision biomarkers reflecting network activity rather than individual protein expression. Network-based approaches could potentially transform immunotherapy success rates from 20-40% to 60-70% of patients through systematic prevention of resistance mechanisms.

Introduction

Cancer immunotherapy has transformed oncological treatment, yet most patients do not achieve durable responses. Haslam and Prasad found that while immune checkpoint inhibitors show remarkable efficacy in hematologic malignancies with response rates of 60-80%, solid tumors present a more challenging landscape, with only 20-40% of patients achieving sustained responses [1]. This disparity reflects the unique capacity of solid tumor microenvironments to establish sophisticated, multi-layered immunosuppressive networks.

The initial success of PD-1/PD-L1 checkpoint inhibitors established a therapeutic paradigm based on individual target inhibition. Robert and colleagues validated this approach when pembrolizumab showed superior outcomes in advanced melanoma [2]. This success naturally extended investigational focus to other immunomodulatory targets, particularly enzymes controlling amino acid metabolism—a fundamental requirement for optimal T-cell function [3].

Indoleamine 2,3-dioxygenase 1 (IDO1) emerged as the archetypal next-generation target based on compelling mechanistic rationale. Munn and Mellor showed that IDO1 controls immune responses through dual mechanisms: depleting tryptophan while simultaneously producing immunosuppressive kynurenine metabolites [4]. The therapeutic logic appeared unassailable - block IDO1, restore tryptophan availability, eliminate kynurenine production, and rescue T-cell function.

However, the phase III ECHO-301 trial delivered a devastating reality check. Long et al. reported that despite achieving unprecedented target engagement rates exceeding 90%, epacadostat showed no clinical benefit when combined with pembrolizumab in patients with metastatic melanoma [5]. This complete absence of therapeutic effect despite near-complete target inhibition fundamentally challenged the single-target paradigm.

Post-hoc analysis revealed the underlying mechanism explaining this paradoxical result. Muller and colleagues found that successful IDO1 inhibition had triggered rapid compensatory activation of alternative tryptophan-degrading enzymes, particularly IL4I1 and TDO2, which functionally substituted for IDO1's immunosuppressive effects [6]. This compensation maintained tryptophan depletion and continued production of immunosuppressive metabolites through alternative biochemical pathways, explaining why robust target engagement failed to produce clinical benefit. The hierarchical organization of these compensation networks and their therapeutic implications are illustrated in Figure 1, which depicts the three-layered regulatory architecture underlying immunotherapy resistance.



Figure 1. Enzymatic Compensation Network Architecture in Cancer Immunotherapy Resistance

Figure 1 illustrates the hierarchical network organization underlying immunotherapy resistance and rational targeting strategies to overcome compensation mechanisms.

Panel A: Three-Layer Regulatory Architecture depicts the hierarchical control system governing immunosuppressive networks.

The epigenetic layer (blue) contains master controllers including SETDB1 (H3K9 methyltransferase), HDAC8 (histone deacetylase), and BRD4 (bromodomain protein) that establish chromatin states controlling multiple pathways simultaneously. The regulatory layer (green) provides dynamic fine-tuning through microRNA-152 (targeting PD-L1/metabolic enzymes), CCAT2 (regulating GLS1 splicing), and SUMOylation (protein modification control). The enzymatic network layer (orange) executes immunosuppressive functions through distinct circuits: tryptophan metabolism (IDO1, IL4I1, TDO2) and alternative pathways (GLS1, ARG1, CD73). Blue arrows indicate hierarchical control flow from upstream regulators to downstream effectors.

Panel B: Compensation Mechanisms demonstrates network responses to therapeutic intervention. **Immediate compensation** (hours-days) shows rapid IL4I1/TDO2 activation following IDO1 inhibition, maintaining immunosuppressive function through alternative enzymes within the same pathway.
Cross-pathway switching (days-weeks) depicts activation of functionally distinct mechanisms (GLS1 glutamine depletion, CD73 adenosine signaling) when primary pathways are blocked. Red arrows indicate direct compensatory pathways revealed by ECHO-301 failure analysis.

Panel C: Network-Based Therapeutic Strategies presents three complementary targeting approaches. **Vertical targeting** (blue) prevents functional redundancy through within-pathway combinations (IDO1+IL4I1+TDO2). **Horizontal targeting** (green) blocks cross-pathway compensation via multi-mechanism combinations (amino acid+purinergic pathways).
Hierarchical targeting (yellow) achieves pan-network disruption through upstream regulatory control (epigenetic + checkpoint combinations).

Mechanisms of Immunotherapy Resistance: A Systems-Level Analysis

Enzymatic Compensation Networks
The ECHO-301 failure revealed that tumors possess sophisticated mechanisms to rapidly activate alternative enzymatic pathways when primary targets are blocked. This represents functional redundancy where multiple pathways achieve identical immunosuppressive outcomes through distinct biochemical mechanisms.
IL4I1-Mediated Compensation: The compensatory role of IL4I1 emerged from detailed mechanistic studies showing its unique secreted function [7]. Rather than operating intracellularly like IDO1, this L-amino acid oxidase generates indole metabolites in the extracellular space, where they activate the aryl hydrocarbon receptor pathway. The resulting shift toward regulatory T-cell dominance creates an alternative immunosuppressive environment that effectively substitutes for lost IDO1 activity [8].
TDO2-Mediated Substitution: Platten and colleagues identified tryptophan 2,3-dioxygenase (TDO2) as another critical compensatory enzyme, showing how this normally liver-restricted enzyme can be upregulated in tumor tissues to maintain tryptophan catabolism when IDO1 is blocked [9]. TDO2 produces the same kynurenine metabolites as IDO1 but operates under different regulatory control mechanisms.
Cross-Pathway Compensation: Beyond functionally similar enzymes, cancer cells exhibit remarkable metabolic flexibility by redirecting amino acid depletion strategies when primary pathways are blocked. When tryptophan becomes unavailable for depletion due to IDO1 inhibition, tumors can upregulate alternative mechanisms. Altman and colleagues characterized glutaminase 1 (GLS1) as catalyzing the rate-limiting step in glutaminolysis [10]. Klysz et al. established that glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cells and regulatory T cells, revealing how GLS1 activation creates immunosuppressive conditions through glutamine competition [11]. The specific compensation mechanisms, temporal patterns, and clinical evidence for these enzymatic networks are summarized in Table 1.
Temporal Dynamics of Network Compensation
Network compensation exhibits distinct temporal patterns crucial for therapeutic intervention design. Jenkins and colleagues characterized how immediate compensation (hours to days) involves post-translational activation of pre-existing alternative enzymes, while delayed compensation (weeks to months) requires transcriptional reprogramming and epigenetic changes [12].
IDO1 inhibition triggers rapid IL4I1 activation through existing macrophage populations within hours, explaining why robust target engagement fails to produce immediate clinical benefit. This rapid compensation occurs through post-translational modifications that activate pre-existing enzyme pools without requiring new protein synthesis.

Delayed compensation involves comprehensive transcriptional reprogramming that establishes new steady-state expression levels of alternative immunosuppressive enzymes. This process requires epigenetic modifications and transcription factor activation that can take weeks to fully establish but creates more stable resistance mechanisms.

Table 1. Enzymatic Compensation Mechanisms in Cancer Immunotherapy Resistance

Enzyme	Function	Substrate → Product	Immune Impact	Compensation Role	Temporal Pattern	Clinical Evidence
IDO1	Tryptophan catabolism	Tryptophan → Kynurenine	T-cell suppression, Treg expansion	Primary target	Baseline	Failed in ECHO-301 (>90% inhibition)[5]
IL4I1	Secreted L-amino acid oxidase	Aromatic amino acids → Indole metabolites	AhR activation, Treg differentiation	Immediate IDO1 substitute	Hours-days	Post-hoc ECHO-301 analysis[6]
TDO2	Alternative tryptophan degradation	Tryptophan → Kynurenine	Maintains kynurenine levels	Direct IDO1 replacement	Hours-days	Preclinical validation[9]
GLS1	Glutaminolysis regulation	Glutamine → Glutamate, α-KG	Th1/Treg imbalance, amino acid starvation	Cross-pathway metabolic switch	Days-weeks	CB-839 combination trials[10]
ARG1	Arginine depletion	Arginine → Ornithine, urea	TCR signaling impairment	Alternative amino acid target	Days-weeks	Metabolic flexibility studies
CD73	Purinergic nucleotidase	AMP → Adenosine	A2A receptor suppression	Non-metabolic compensation	Days-weeks	Oleclumab combination data

Upstream Regulatory Mechanisms: Master Controllers of Network Function

Epigenetic Master Control Systems

Jones and colleagues showed that targeting the cancer epigenome offers opportunities to modulate multiple immunosuppressive pathways simultaneously, revealing how epigenetic modifiers function as master orchestrators of immune evasion networks [13]. These upstream controllers can simultaneously regulate the expression of multiple immunomodulatory enzymes.

SETDB1-Mediated Coordinated Control: Among epigenetic controllers, SETDB1 functions as a histone H3 lysine 9 methyltransferase, establishing repressive chromatin domains that simultaneously suppress immune activation genes while promoting immunosuppressive enzyme expression including IDO1 and ARG1.

HDAC8-Mediated Dual Regulation: Li et al. revealed how HDAC8 operates through a different but complementary mechanism, removing acetyl groups from both histones and key proteins like PD-L1 [14]. HDAC8 directly deacetylates PD-L1 at lysine 263, promoting nuclear translocation and transcriptional upregulation, while simultaneously deacetylating histones at promoters of immunosuppressive enzyme genes. This dual mechanism enables single epigenetic modifiers to control both checkpoint ligand expression and metabolic enzyme networks.

Post-Translational Network Dynamics

Post-translational modifications provide dynamic, reversible control over immunomodulatory enzyme activity, enabling rapid network reconfiguration in response to therapeutic pressure. Zhang et al. identified lactylation as establishing a direct connection between tumor metabolism and immune evasion gene expression [15].

Lactylation-Mediated Metabolic Control: Lactylation of histone H3 lysine 18 in tumor-associated macrophages enhances transcription of ARG1, IL4I1, and other immunosuppressive enzymes while promoting

M2 macrophage polarization. This mechanism directly links tumor metabolic output to immune suppression gene expression, creating a feed-forward loop that strengthens immunosuppressive networks.

SUMOylation-Mediated Dynamic Regulation: Geiss-Friedlander and Melchior characterized SUMOylation as providing dynamic control over enzyme stability and subcellular localization through reversible protein modifications [16]. SUMOylation of transcription factors regulates their ability to activate immunosuppressive enzyme expression programs.

Non-Coding RNA Fine-Tuning Networks

Non-coding RNAs function as rheostats that fine-tune immunomodulatory enzyme expression, serving as the final regulatory layer determining precise expression levels and environmental responses. Chen and colleagues found that the microRNA-200/ZEB1 axis controls tumor cell PD-L1 expression and intratumoral immunosuppression [17].

MicroRNA-152 Regulatory Axis: MicroRNA-152 provides tumor-suppressive regulation by directly targeting the 3'-untranslated region of PD-L1 while also targeting additional immune evasion genes, including CD73 and metabolic enzymes. The p53-miR-152-PD-L1 axis establishes a direct connection between tumor suppressor pathway integrity and immune evasion control.

CCAT2-Mediated Splicing Control: Redis et al. identified the long non-coding RNA CCAT2 as a key regulator of GLS1 splicing through interaction with the CFIm protein complex, promoting the preferential expression of the more enzymatically active GAC splice variant [18]. The complete spectrum of upstream and post-transcriptional regulators controlling immunotherapy resistance is detailed in Table 2.

Table 2. Upstream and Post-Transcriptional Regulators in Immunotherapy Resistance

Regulator	Regulatory Type	Mechanism	Primary Targets	Network Control	Therapeutic Approach	Clinical Status
SETDB1	Epigenetic master	H3K9 methyltransferase	IDO1, ARG1, antigen presentation	Coordinated immune-suppression	Methyltransferase inhibitors	Preclinical
HDAC8	Epigenetic master	Histone/protein deacetylase	PD-L1 (K263), metabolic enzymes	Dual checkpoint/metabolic control	Selective HDAC inhibitors	Phase II trials
BRD4	Epigenetic master	Bromodomain chromatin reader	Immuno-suppressive enhancers	Transcriptional amplification	BET inhibitors (JQ1, OTX015)	Phase I/II
Lactylation	Post-translational	Histone H3K18 modification	ARG1, IL4I1, M2 genes	Metabolism-epigenome coupling	Lactate pathway targeting	Preclinical
SUMOylation	Post-translational	Small ubiquitin-like modification	Transcription factors, enzyme stability	Dynamic activity regulation	SUMO pathway inhibitors	Research phase
miR-152	Non-coding RNA	mRNA 3'-UTR targeting	PD-L1, CD73, metabolic enzymes	Tumor suppressor-immune axis	miRNA replacement therapy	Preclinical
CCAT2	Non-coding RNA	Splicing regulation via CFIm	GLS1 isoform (GAC variant)	Enhanced glutaminolysis	Antisense oligo-nucleotides	Research phase

Network-Based Therapeutic Strategies

Rational Combination Design Principles

Understanding compensation networks enables rational design of combination therapies that anticipate and prevent resistance mechanisms. Rather than simply adding more drugs, successful strategies must be designed around the specific compensation mechanisms that tumors employ—whether through backup enzymes in the same pathway, alternative metabolic routes, or upstream regulatory rewiring.

Vertical Combinations: When enzymes within the same pathway can substitute for each other—as IL4I1 and TDO2 do for IDO1—vertical targeting through multi-enzyme inhibition prevents this functional redundancy (IDO1 + IL4I1 + TDO2 for complete tryptophan metabolism blockade).

Horizontal Combinations: Cross-pathway compensation, where entirely different suppressive mechanisms activate, requires horizontal approaches that simultaneously disrupt amino acid metabolism and alternative systems like purinergic signaling.
Hierarchical Combinations: The most elegant strategy targets hierarchical controllers that orchestrate multiple pathways, potentially achieving broad network disruption through fewer therapeutic agents. Representative examples of these network-based therapeutic strategies, along with their development status and expected outcomes, are presented in Table 3.

Table 3. Network-Based Therapeutic Strategies for Cancer Immunotherapy

Strategy Type	Targeting Approach	Representative Combinations	Mechanistic Rationale	Development Status	Expected Outcome
Vertical	Within-pathway redundancy	IDO1 + IL4I1 + TDO2 inhibitors	Prevent functional substitution in tryptophan circuit	Phase I planned 2025-2027	Complete pathway blockade
Vertical	Checkpoint redundancy	Anti-PD-1 + Anti-CTLA-4 + Anti-LAG-3	Block multiple immune checkpoints	Ongoing trials	Enhanced T-cell activation
Horizontal	Cross-pathway switching	CB-839 (GLS1) + Oleclumab (anti-CD73)	Prevent metabolic-to-purinergic compensation	Phase I/II combinations	Multi-mechanism disruption
Horizontal	Multi-metabolite	IDO1 inhibitor + CB-839 (GLS1) + ARG1 inhibitor	Block amino acid competition switching	Preclinical/ Phase I	Comprehensive metabolic restoration
Hierarchical	Transcriptional hub	SY-1365 (CDK7) + Anti-PD-1	Dual transcription/cell cycle control	Phase I ongoing	Multi-pathway modulation
Hierarchical	Epigenetic master	Vorinostat (HDAC) + Anti-PD-1	Upstream regulatory network control	Multiple Phase II trials	Pan-network disruption
Hierarchical	Chromatin control	JQ1/OTX015 (BRD4) + Checkpoint blockade	Master chromatin-level regulation	Phase I/II studies	Coordinated gene reprogramming
Adaptive	Real-time monitoring	AI-guided sequential protocols	Dynamic combination based on network evolution	Technology development	Prevention-based resistance management

Novel Enzyme Targets for Network Disruption

CDK7 as a Dual Hub Target: Wang et al. found that CDK7 inhibition can trigger immune-response signaling while reducing PD-L1 expression, suggesting synergy with checkpoint blockade [19]. CDK7 serves as a dual transcription/cell cycle hub that offers unique opportunities for network disruption through its control of both transcriptional programs and cell cycle progression.

IDH1 as a Metabolic-Epigenetic Bridge: IDH1 mutations create vulnerabilities that bridge metabolism and epigenetic regulation. Wild-type IDH1 produces α-ketoglutarate, a cofactor for DNA and histone demethylases, while mutant IDH1 produces the oncometabolite 2-hydroxyglutarate, which inhibits these same enzymes. This creates opportunities for targeting both metabolic and epigenetic aspects of immune evasion networks.

Spatial-Temporal Network Organization
Lewis and colleagues used spatial omics technologies to show that immunomodulatory enzyme networks are organized heterogeneously across tumor architecture, with distinct expression territories that create complex compensation patterns [20]. This spatial organization explains why systemic enzyme inhibition may succeed in some tumor regions while failing in others.

Multiplexed protein imaging technologies reveal that multiple immunosuppressive enzymes cluster together in specific tumor regions, creating synergistic immunosuppression that explains why single-target approaches fail to effectively disrupt local immune suppression. These "immunosuppressive niches" require coordinated multi-target intervention to achieve meaningful therapeutic disruption.

Clinical Implications and Future Directions

Biomarker Development Requirements

Network-based approaches require biomarkers that reflect network activity rather than individual protein expression levels. Topology biomarkers measuring network connectivity patterns, compensation signatures predicting alternative pathway activation, and network activity scores quantifying overall immunosuppressive network function represent critical developments for precision network medicine.

Ongoing Clinical Development

Current clinical trials provide proof-of-concept for network-based approaches. CB-839 (telaglenastat) is in Phase I-II trials across multiple solid tumor types, with particular focus on combination strategies [21]. SY-1365 has entered Phase I trials for advanced solid tumors, providing proof-of-concept for targeting transcriptional-cell cycle hubs as network disruption strategies [22].

Technology Integration Requirements

Clinical implementation requires widespread adoption of spatial transcriptomics platforms. Current 10x Genomics Visium technology provides 55-micrometer resolution, enabling identification of patients most likely to benefit from specific combination strategies. Graph neural networks specifically designed for biological network analysis require clinical validation through partnerships between academic institutions, technology companies, and pharmaceutical developers. The comprehensive clinical workflow for implementing network-based adaptive immunotherapy is outlined in Figure 2, which demonstrates the three-stage transformation from static single-target approaches to dynamic, AI-guided precision medicine.



Figure 2. Network-Based Clinical Implementation Strategy for Adaptive Immunotherapy

Figure 2 outlines the clinical workflow transforming static single-target approaches into adaptive network-based immunotherapy through three integrated stages.

Stage 1: Patient Stratification establishes precision network medicine through comprehensive tumor profiling. Spatial omics profiling employs 10x Genomics Visium (55-micrometer resolution) and multiplexed protein imaging to map enzyme network organization across tumor architecture. AI-driven network topology analysis uses graph neural networks to identify compensation circuit patterns, immunosuppressive niches where multiple enzymes cluster synergistically, and individual network vulnerabilities. Network stratification categorizes patients based on dominant resistance mechanisms, enabling personalized combination selection. Timeline: 2-5 days for complete characterization, clinical deployment 2025-2028.

Stage 2: Rational Treatment Design implements mechanism-based combination strategies. Vertical targeting (V symbol) combines pathway-redundant enzymes (IDO1+IL4I1+TDO2) to prevent functional substitution. Horizontal targeting (H symbol) addresses cross-pathway compensation through multi-mechanism combinations (CB-839+anti-CD73) blocking metabolic switching. Hierarchical targeting (↑ symbol) modulates upstream controllers (CDK7+PD-1, HDAC+checkpoint blockade) achieving pan-network disruption. Selection algorithms match patient network profiles to optimal combination strategies.

Stage 3: Adaptive Monitoring enables dynamic treatment optimization. Real-time network surveillance tracks compensation pathway activation through circulating biomarkers, liquid biopsy platforms, and serial spatial profiling. AI-powered compensation detection identifies emerging alternative pathway activation before clinical progression. Dynamic therapy adjustment implements protocol modifications based on network evolution, preventing rather than responding to resistance mechanisms.

Expected Clinical Impact

Network-based approaches have the potential to extend immunotherapy benefits to the 60-80% of solid tumor patients who currently do not respond to checkpoint inhibitors. By systematically addressing compensation mechanisms, response rates could potentially approach those achieved in hematologic malignancies.

Conclusions

The dramatic failure of IDO1 inhibitors in ECHO-301, despite achieving >90% target engagement, has fundamentally transformed our understanding of cancer immunotherapy resistance. What initially appeared as a devastating clinical failure has illuminated the path toward more effective, scientifically-grounded therapeutic strategies.

Our analysis establishes that successful immunotherapy requires network-based interventions that anticipate and prevent compensation mechanisms. The path forward requires moving beyond single-target thinking toward combination approaches that account for network resilience. Three complementary strategies emerge: vertical targeting to prevent functional redundancy within pathways, horizontal targeting to block cross-pathway metabolic switching, and hierarchical targeting to control upstream regulatory networks governing multiple immunosuppressive programs simultaneously.

The scientific foundation is robust, with clear evidence from ECHO-301 post-hoc analysis, compensation mechanism studies, and emerging spatial omics technologies. Network-based immunotherapy moves beyond incremental improvement toward rational, mechanism-based cancer treatment that addresses the biological principles underlying therapeutic resistance.

Implementation requires coordinated action: immediate establishment of spatial omics profiling infrastructure, prioritization of vertical combination trials testing IDO1 + IL4I1 inhibition, development of AI platforms for combination selection, and standardization of network activity biomarkers across institutions.

The clinical opportunity is substantial: most solid tumor patients remain unresponsive to current immunotherapies, despite remarkable success in blood cancers. Network-based approaches offer a scientific rationale for closing this gap by addressing the fundamental compensation mechanisms that solid tumors use to evade immune attack. By systematically addressing compensation mechanisms through rational combination design, we can potentially achieve the remarkable success rates already seen in hematologic malignancies.

Conflicts of Interest

The authors declare no conflicts of interest related to this work. No financial or non-financial benefits have been received or are anticipated from any individual or organization directly or indirectly associated with the content of this article.

Ethics Approval and Consent to Participate

Not applicable. This review article does not involve studies with human participants, animal subjects, or clinical interventions.

Acknowledgements

The authors gratefully acknowledge the support from the institutional libraries for providing access to scientific databases and literature resources, which significantly facilitated the preparation of this review.

References

1. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535.
2. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-1117. doi:10.1016/S0140-6736(14)60958-2.
3. Buck MD, O'Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med. 2015;212(9):1345-1360. doi:10.1084/jem.20151159.
4. Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37(3):193-207. doi:10.1016/j.it.2016.01.002.
5. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus pembrolizumab alone in unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a Phase 3, randomized, double-blind study. Lancet Oncol. 2019;20(8):1083-1097. doi:10.1016/S1470-2045(19)30337-9.
6. Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to tumor escape from immune control: A review of combinational IO strategies. Front Immunol. 2018;9:386. doi:10.3389/fimmu.2018.00386.
7. Sadik A, Somarribas Patterson LF, Öztürk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 is a metabolic immune checkpoint that activates the aryl hydrocarbon receptor. Cell. 2020;182(5):1252-1270.e34. doi:10.1016/j.cell.2020.07.038.
8. Duhalde Vega M, Skuli N, Simonelli L, Weckel A, Smal G, Pirnay T, et al. IL4I1 is expressed in tumor-associated macrophages and is a poor prognostic marker in melanoma. J Invest Dermatol. 2021;141(2):453-462. doi:10.1016/j.jid.2020.06.028.
9. Platten M, Nollen EAA, Röhrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer and neurodegeneration. Nat Rev Drug Discov. 2019;18(5):379-401. doi:10.1038/s41573-019-0016-5.
10. Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619-634. doi:10.1038/nrc.2016.71.
11. Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, et al. Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell populations. Sci Signal. 2015;8(396):ra97. doi:10.1126/scisignal.aab2610.
12. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9-16. doi:10.1038/bjc.2017.434.
13. Jones PA, Issa JPJ, Baylin S. Targeting the cancer epigenome. Nat Rev Genet. 2016;17(10):630-641. doi:10.1038/nrg.2016.93.
14. Li L, Wang X, Wang Z, Ho GYF, Pedram B, Yu Q, et al. HDAC8 drives the nuclear localization of PD-L1 and potentiates T cell exclusion in pancreatic cancer. Nat Commun. 2021;12(1):3431. doi:10.1038/s41467-021-23748-0.
15. Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574(7779):575-580. doi:10.1038/s41586-019-1678-1.
16. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007;8(12):947-956. doi:10.1038/nrm2293.
17. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, et al. MicroRNA-152 mediates p53-dependent PD-L1 regulation. Mol Cancer Res. 2018;16(1):86-95. doi:10.1158/1541-7786.MCR-17-0346.
18. Redis RS, Vela LE, Lu W, Ferreira AM, Chandrasekaran KS, Das S, et al. Allele-specific repression of mutant TGFBR2 by mutant p53 via the lncRNA CCAT2 promotes allele-specific glutaminase splicing and glioma tumorigenesis. Nature. 2016;541(7635):575-579. doi:10.1038/nature21053.
19. Wang Y, Liu Y, Chen Y, Sun J, Han W, Zang Y, et al. CDK7-dependent transcriptional regulation in cancer: roles and opportunities for therapy. Mol Cancer. 2022;21(1):61. doi:10.1186/s12943-022-01502-4.

20. Lewis SM, Asselin-Labat ML. Spatial omics in cancer: integrating histology and molecular profiling. Nat Rev Genet. 2021;22(7):472-487. doi:10.1038/s41576-021-00335-w.
21. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890-901. doi:10.1158/1535-7163.MCT-13-0870.
22. Syros Pharmaceuticals. A Phase 1, Open-Label, Dose Escalation and Expansion Trial of the Safety and Efficacy of SY-1365, a Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors (NCT03134638). ClinicalTrials.gov.